Literature DB >> 15127417

Results of treatment of fifty-six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: a report from The Intergroup Rhabdomyosarcoma Study-IV, 1991-1997.

R Beverly Raney1, Julie A Stoner, David O Walterhouse, Richard J Andrassy, Sarah S Donaldson, Fran Laurie, William H Meyer, Stephen J Qualman, William M Crist.   

Abstract

BACKGROUND: We reviewed 56 IRS-IV patients with localized rhabdomyosarcoma [RMS] of the retroperitoneum/pelvis to assess outcome and prognostic factors, including the value of initially excising >or=50% of the tumor (debulking) before chemotherapy.
METHODS: Patients had embryonal RMS [N=38], alveolar RMS [N = 7], RMS not otherwise specified [NOS, N = 7], or undifferentiated sarcoma [N = 4]. Fifteen patients were debulked; 41 patients were biopsied. All received VAC; most received radiotherapy.
RESULTS: Estimated 5-year failure-free survival [FFS] and overall survival rates were 70 and 75%, respectively. FFS rates were better for patients <10 years old and those with embryonal RMS compared to alveolar RMS/undifferentiated sarcoma. After adjusting for age and histological differences, FFS was better for patients whose tumor was debulked prior to beginning therapy [P = 0.02].
CONCLUSIONS: These results are superior to those of previous protocols for patients with RMS of the retroperitoneum/pelvis. Initial excision of >or=50% of the tumor may be associated with increased FFS. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 15127417     DOI: 10.1002/pbc.20012

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  6 in total

Review 1.  What is new in rhabdomyosarcoma management in children?

Authors:  Yasmin Gosiengfiao; Jennifer Reichek; David Walterhouse
Journal:  Paediatr Drugs       Date:  2012-12-01       Impact factor: 3.022

Review 2.  What we have learned: the impact of quality from a clinical trials perspective.

Authors:  Thomas J FitzGerald
Journal:  Semin Radiat Oncol       Date:  2012-01       Impact factor: 5.934

3.  Optimal surgical treatment and urological outcomes in boys with pelvic and urogenital rhabdomyosarcomas and soft tissue sarcomas.

Authors:  Tomoro Hishiki; Takeshi Saito; Tetsuya Mitsunaga; Mitsuyuki Nakata; Elena Terui; Shugo Komatsu; Naoko Mise; Kazuaki Harada; Jun Iwai; Yasuyuki Higashimoto; Yuri Okimoto; Harumi Kakuda; Hidemasa Ochiai; Moeko Hino; Sumie Homma; Yuichi Osa; Hideo Yoshida
Journal:  Pediatr Surg Int       Date:  2013-10       Impact factor: 1.827

4.  Prognostic factors of pediatric pelvic and genitourinary rhabdomyosarcoma: An analysis based on SEER database.

Authors:  Jiheng Wu; Xinyi Shou; Jiabin Cai; Junqing Mao; Jianqin Qian; Jinhu Wang; Shaoqing Ni
Journal:  Front Oncol       Date:  2022-09-05       Impact factor: 5.738

5.  Embryonal prostatic rhabdomyosarcomas disguised presentation in an adolescent male: a case report.

Authors:  Nishith K Singh; Malatesha Gangappa; Vineet Gupta; Anant Mohan
Journal:  Cases J       Date:  2009-08-26

6.  Pleomorphic rhabdomyosarcoma infiltrating thoracic spine in a 59-year-old female patient: Case report.

Authors:  Matthias Spalteholz; Jens Gulow
Journal:  GMS Interdiscip Plast Reconstr Surg DGPW       Date:  2017-07-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.